Skip to Content
Merck
CN
  • Conservative medical treatment of ovarian hyperstimulation syndrome: a single center series and cost analysis study.

Conservative medical treatment of ovarian hyperstimulation syndrome: a single center series and cost analysis study.

Acta obstetricia et gynecologica Scandinavica (2013-03-05)
Gemma Casals, Francisco Fábregues, Marco Pavesi, Vicente Arroyo, Juan Balasch
ABSTRACT

To present the results of a large series of patients with ovarian hyperstimulation syndrome treated with a conservative medical approach and to compare the cost of this treatment with outpatient management with paracentesis according to published data. Retrospective case series and cost analysis study using a decision-tree model. University hospital. 496 consecutive patients with ovarian hyperstimulation syndrome treated in our center from 1991 to 2010. All patients were treated with a conservative medical approach: (a) conservative outpatient approach: bed rest and a low-sodium diet or (b) hospitalized patients: bed rest, low-sodium diet, 20% albumin (60 g/day) and furosemide (20 mg/8 h). Percentage of admissions, length of hospital stay and readmissions. Total cost of each therapeutic approach. (a) Conservative outpatient approach (n = 377): all cases solved without admission. (b) Hospitalized patients with conservative medical treatment (n = 119): 2.8 days of mean hospital stay, no patient required paracentesis or admission to intensive care unit. Readmissions: Five patients (4.2%) resolved on restarting medical treatment. (c) Cost-analysis comparison: Cost of the outpatient approach with paracentesis: US$980 (range US$519-3557). Cost of conservative medical treatment: US$570 (range US$232-1640). Ovarian hyperstimulation syndrome can be safely managed with a conservative medical approach, which was not found to be more expensive than outpatient management with paracentesis.

MATERIALS
Product Number
Brand
Product Description

Supelco
Furosemide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®